MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Voyager Therapeutics Company Profile (NASDAQ:VYGR)

Consensus Ratings for Voyager Therapeutics (NASDAQ:VYGR) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $29.33 (166.91% upside)

Analysts' Ratings History for Voyager Therapeutics (NASDAQ:VYGR)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016WedbushReiterated RatingOutperform$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Wells FargoInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/25/2016Chardan CapitalUpgradeSell -> Neutral$20.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Voyager Therapeutics (NASDAQ:VYGR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016        
5/12/2016Q1($0.38)$0.29ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2016Q4($0.55)($0.67)$4.94 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Voyager Therapeutics (NASDAQ:VYGR)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Voyager Therapeutics (NASDAQ:VYGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Voyager Therapeutics (NASDAQ:VYGR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/14/2016Steven M PaulCEOBuy10,000$14.07$140,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Voyager Therapeutics (NASDAQ:VYGR)
DateHeadline
06/22/16 07:06 PMVoyager Therapeutics Announces Interim Phase 1b Surgical Results for VY-AADC01 in Advanced Parkinson’s Disease
06/22/16 07:06 PMVoyager Therapeutics (VYGR) Offers Interim Phase 1b Data on VY-AADC01 in PD Patients
06/22/16 08:03 AMVoyager Therapeutics Reveals Interim Phase 1b Surgical Results For VY-AADC01 In Advanced Parkinson's Disease -
06/16/16 03:50 PMVOYAGER THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/31/16 07:00 AMVoyager (VYGR) Looks Good: Stock Adds 6.8% in Session -
05/23/16 12:39 PMVoyager Therapeutics, Inc. :VYGR-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
05/23/16 09:40 AMHot Alert: ConocoPhillips (NYSE:COP), Voyager Therapeutics, Inc. (NASDAQ:VYGR), Nortek Inc. (NASDAQ:NTK ... - KC Register - Hot Alert: ConocoPhillips (NYSE:COP), Voyager Therapeutics, Inc. (NASDAQ:VYGR), Nortek Inc. (NASDAQ:NTK ...KC RegisterVoyager Therapeutics, Inc. (NASDAQ:VYGR) reported its first quarter 2016 financial results and provided an update on its advanced Parkinson's disease program, VY-AADC01. For the first quarter ended March 31, 2016, Voyager reported a net loss of $7.2 ...and more »
05/21/16 09:44 AMTop Wall Street Stories: Voyager Therapeutics, Inc. (NASDAQ:VYGR), New Gold, Inc. (NYSEMKT:NGD), NVIDIA ... - KC Register - Top Wall Street Stories: Voyager Therapeutics, Inc. (NASDAQ:VYGR), New Gold, Inc. (NYSEMKT:NGD), NVIDIA ...KC RegisterVoyager Therapeutics, Inc. (NASDAQ:VYGR) said that, it will present 2016 UBS Global Healthcare Conference on 23 May. On Wednesday Voyager Therapeutics, Inc. (NASDAQ:VYGR) share price closed at $11.00. Company return on equity (ROE) is ...
05/12/16 06:17 AMVoyager Therapeutics reports 1Q loss -
05/12/16 06:17 AMVoyager Therapeutics Provides First Quarter 2016 Investor Update - [at noodls] - Enrollment Completed in 2 Cohort of Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson's Disease VY-AADC01 Interim Phase 1b Results to be Presented at 20 International Congress of Parkinson's ...
05/12/16 06:07 AMQ1 2016 Voyager Therapeutics Inc Earnings Release - Before Market Open -
05/11/16 07:52 AMVoyager Therapeutics to Present at Upcoming Investor Conferences - [at noodls] - CAMBRIDGE, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central ...
05/05/16 07:21 AMVoyager Therapeutics to Host First Quarter 2016 Investor Update Call - [at noodls] - CAMBRIDGE, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central ...
04/29/16 08:58 AMVoyager Therapeutics Highlights Programs In Parkinson's Disease And ALS; Announces Expansion Of CNS Pipeline At R&D Day - Two New Gene Therapy Programs Targeting Tau and Nav1.7 Announced CAMBRIDGE, Mass., April 29, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of ...
04/29/16 07:29 AMVoyager Therapeutics Highlights Programs in Parkinson’s Disease and ALS; Announces Expansion of CNS Pipeline at R&D Day - [at noodls] - Top-Line Proof-of-Concept Clinical Data for Parkinson's Disease Program (VY-AADC01) Remains on Track for the Fourth Quarter of 2016 IND Filing for ALS Program (VY-SOD101) Targeted for Late 2017 Two New ...
04/26/16 08:16 AMToday's Bell Ringer, April 26, 2016 -
04/25/16 10:49 AMVoyager Therapeutics (Nasdaq: VYGR) to Ring The Nasdaq Stock Market Opening Bell - [at noodls] - ADVISORY, April 25, 2016 (GLOBE NEWSWIRE) -- What: Voyager Therapeutics (Nasdaq:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous ...
04/25/16 09:00 AMVoyager Therapeutics Incorporated (NASDAQ:VYGR) Short Interest Increased By 11.08% - The stock increased 2.79% or $0.33 on April 22, hitting $12.16. About 27,242 shares traded hands. Voyager Therapeutics Inc (NASDAQ:VYGR) has risen 6.00% since March 25, 2016 and is uptrending. It has outperformed by 0.91% the S&P500. Voyager Therapeutics ...
04/14/16 08:53 AMBig Moving Stocks, April 14 – VYGR, PYDS, EMKR, GPRO, LSCC, RESN, CYBE, CONN, DMTX, ARGS - Voyager Therapeutics Inc (VYGR) traded at $13.48 + 2.50 (22.76 percent) on 88,819 total share volume. The company is -38.45 percent year-to-date, and — during the past four quarters. Payment Data Systems Inc (PYDS) traded at $2.05 + 0.34 (19.88 percent ...
04/14/16 07:29 AMVoyager Therapeutics to Host R&D Day and Webcast on April 29, 2016 - [at noodls] - CAMBRIDGE, Mass., April 14, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central ...
04/13/16 08:57 AMBusiness Update: Wednesday Big Movers – LBTYB, HPJ, VYGR, CSTE, ASYS, CARV, CRBP, SBBP, TTNP - The company is -21.67 percent Year to Date (YTD), and -45.22 percent in the past four quarters. Voyager Therapeutics Inc (VYGR) traded at $10.90 + 1.26 (13.07 percent) on 393,760 total stock volume. The company is -50.23 percent Year to Date (YTD), and ...
04/13/16 07:15 AMVoyager Therapeutics (VYGR) Jumps: Stock Rises 13.9% -
03/23/16 12:04 PMVOYAGER THERAPEUTICS, INC. Financials -
03/17/16 12:13 PMEdited Transcript of VYGR earnings conference call or presentation 17-Mar-16 12:30pm GMT -
03/17/16 07:30 AMVoyager Therapeutics Inc Earnings Call scheduled for 8:30 am ET today -
03/17/16 06:16 AMVoyager Therapeutics reports 4Q loss -
03/17/16 06:07 AMQ4 2015 Voyager Therapeutics Inc Earnings Release - Before Market Open -
03/17/16 06:00 AMVoyager Therapeutics Provides Fourth Quarter and Full Year 2015 Investor Update - [GlobeNewswire] - Top-line Clinical Proof-of-Concept Data for VY-AADC01 for Advanced Parkinson’ s Disease On Track for Release in the Fourth Quarter of 2016. Strong Cash Position Projected to Support Operations into 2019. ...
03/14/16 08:18 AMVoyager Therapeutics To Present At Alliance For Regenerative Medicine's 4th Annual Cell & Gene Therapy Investor Day - CAMBRIDGE, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that Steven ...
03/14/16 07:00 AMVoyager Therapeutics to Present at Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day - [GlobeNewswire] - CAMBRIDGE, Mass., March 14, 2016-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system, today announced ...
03/10/16 07:00 AMVoyager Therapeutics to Host Fourth Quarter and Full Year 2015 Investor Update Call - [GlobeNewswire] - CAMBRIDGE, Mass., March 10, 2016-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system, today announced ...
03/03/16 04:33 PMHottest Manufacturing Stocks Now – STML GLF BLPH WPRT - Bioamber Inc (BIOA): BIOA stock is up 14.25% today. Revance Therapeutics Inc (RVNC): RVNC stock is up 12.24% today. Voyager Therapeutics (VYGR): VYGR stock is up 10.27% today. Cerulean Pharma Inc (CERU): CERU stock is up 11.88% today. Some of the biggest ...
03/02/16 07:44 AMThese Stocks are Struggling at the Close – OCN, PTCT, OPWR, GB, RNET, VYGR, PN - The company traded at $11.66 – 1.54 (11.67 pct) on 185,662 total stock volume. Voyager Therapeutics Inc (VYGR) posted a new low of 8.12 above a previous 52 week low of 8.76. The company traded at $8.50 – 1.07 (11.18 pct) on 40,712 total stock volume.
03/01/16 04:31 PMBiggest Movers in Manufacturing Stocks Now – LXU BTX LXRX KITE - Some of the biggest losers among Manufacturing stocks include: Aurinia Pharmaceuticals Inc (AUPH): AUPH stock is down 12.24% today. Voyager Therapeutics (VYGR): VYGR stock is down 12.23% today. Flamel Technologies S.A. (FLML): FLML stock is down 10.08% today.
02/29/16 07:00 AMVoyager Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference - [GlobeNewswire] - CAMBRIDGE, Mass., Feb. 29, 2016-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system, today announced ...
02/03/16 06:00 AMWhat recent gene therapy offerings tell us about ​today’s Editas IPO -
02/02/16 05:03 PM6:03 pm Voyager Therapeutics promotes Jeff Goater to CFO -
02/02/16 05:00 PMVoyager Therapeutics Promotes Jeff Goater to Chief Financial Officer - [GlobeNewswire] - CAMBRIDGE, Mass., Feb. 02, 2016-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system, today announced ...
01/25/16 12:59 PMChardan Upgrades Voyager Therapeutics, But Still Sees Parkinson's Drug Issues - Chardan Capital Markets recently issued a company note on Voyager Therapeutics Inc. (NASDAQ: VYGR) after recent stock underperformance relative to its key competitors in the NASDAQ Biotechnology Index. Analysts at Chardan upgraded Voyager Therapeutics to Neutral and lowered their price target from $20 to $15. Gbola Amusa, Head of Healthcare Research at Chardan, wrote, "We now reiterate our previously-published reasons VYGR's lead asset, VY-AADC01. is likely to fail to produce proof-of-concept data in 2H16 and will see delays beyond consensus launch expectations of 2020E...we have reduced our probability of VY-AADC01 launching from 25 percent to 15 percent, ...Full story available on Benzinga.com
01/25/16 04:27 AMVoyager Therapeutics upgraded by Chardan Capital Markets -
01/16/16 03:23 PMUS IPO Weekly Recap: The only IPO delays as the market falls for the second straight week - and Voyager Therapeutics (VYGR), which went public on November 10, 2015. Red Rock Resorts (RRR), formerly Station Casinos, operator of 21 casino and entertainment properties in Las Vegas, changed its name and disclosed that it would list on the Nasdaq ...
01/11/16 02:05 PM​Biotech stock slide stretches into its sixth straight day -
12/18/15 07:22 AMVoyager Therapeutics Added to Russell 2000®, 3000® and Global Indexes - [at noodls] - , (GLOBE NEWSWIRE) -- (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that it has been ...
12/17/15 04:06 PMVoyager Therapeutics Reports Third Quarter 2015 Financial Results - [at noodls] - Initial public offering raised in net proceeds Proof-of-concept data for lead clinical program, VY-AADC01, for Parkinson's disease expected in second half of 2016 , (GLOBE NEWSWIRE) -- (NASDAQ:VYGR), a ...
12/17/15 03:17 PMVOYAGER THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -
12/17/15 12:07 PM5 Biggest Losers from the Fed Rate Hike -
12/07/15 08:21 AMWedbush Likes Voyager's Gene Therapy Pipeline, Initiates At Outperform -
11/16/15 03:48 PMVOYAGER THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Finan -
11/16/15 03:11 PMVoyager Therapeutics Announces Closing of Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares - [at noodls] - CAMBRIDGE, Mass., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central ...
11/13/15 05:46 AMVoyager Therapeutics Announces Pricing of Initial Public Offering - [at noodls] - CAMBRIDGE, Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system ...
About Voyager Therapeutics

Voyager Therapeutics logoVoyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's product pipeline includes programs for Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer's disease and severe, chronic pain. Its products include VY-AADC01 for Advanced Parkinson's Disease, VY-SOD101 for Monogenic amyotrophic lateral sclerosis (ALS), VY-FXN01 for Friedreich's Ataxia, VY-HTT01 for Huntington's Disease and VY-SMN101 for spinal muscular atrophy (SMA). VY-AADC01 consists of the AAV2 capsid, which has been used in multiple adeno-associated virus (AAV) gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the AADC transgene.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VYGR
  • CUSIP:
Key Metrics:
  • Previous Close: $10.99
  • 50 Day Moving Average: $12.85
  • 200 Day Moving Average: $12.70
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $293.97M
  • Current Quarter EPS Consensus Estimate: $-1.54 EPS
Additional Links:
Voyager Therapeutics (NASDAQ:VYGR) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha